Big Pharma split over benefit of mega-merger, says FT

2 June 2009

The pharmaceutical industry has been divided in recent months by the question of whether mega-mergers are the way forward, the UK Financial  Times reports.

The recent economic crisis has led to a burst of M&A activity, with  Pfizer acquiring Wyeth for $68.0 billion, USA-based Merck & Co buying  Schering-Plough in a $41.1-billion reverse takeover and Swiss drug major  Roche taking full control of its US affiliate Genentech in a  $46.8-billion deal (Marketletters passim).

Can big pharma become too big?

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Company News Directory



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight